Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement - PubMed (original) (raw)
Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement
Daniel Ajona et al. Cancer Res. 2004.
Abstract
The complement system is important in immunosurveillance against tumors. However, malignant cells are usually resistant to complement-mediated lysis. In this study, we examine the expression of factor H, an inhibitor of complement activation, and factor H-like protein 1 (FHL-1), its alternatively spliced form, in lung cancer. We also evaluate the potential effect of factor H/FHL-1 in the protection of lung cancer cells against the activation of the complement cascade. By Northern blot analysis we demonstrate a high expression of factor H and FHL-1 in most non-small cell lung cancer cell lines, although neuroendocrine pulmonary tumors (small cell lung carcinoma and carcinoid cell lines) had undetectable levels. Western blot analysis of conditioned medium showed the active secretion of factor H and FHL-1 by cells that were positive by Northern blot. Expression of factor H/FHL-1 mRNA was also shown in a series of non-small cell lung cancer biopsies by in situ hybridization. Interestingly, many cultured lung cancer cells were able to bind fluorescence-labeled factor H to their surfaces. Deposition of C3 fragments from normal human serum on H1264, a lung adenocarcinoma cell line, was more efficient when factor H/FHL-1 activity was blocked by specific antibodies. Blocking factor H/FHL-1 activity also enhanced the release of anaphylatoxin C5a and moderately increased the susceptibility of these cells to complement-mediated cytotoxicity. In summary, we demonstrate the expression of factor H and FHL-1 by some lung cancer cells and analyze the contribution of these proteins to the protection against complement activation.
Similar articles
- Group A streptococcal phagocytosis resistance is independent of complement factor H and factor H-like protein 1 binding.
Kotarsky H, Gustafsson M, Svensson HG, Zipfel PF, Truedsson L, Sjöbring U. Kotarsky H, et al. Mol Microbiol. 2001 Aug;41(4):817-26. doi: 10.1046/j.1365-2958.2001.02496.x. Mol Microbiol. 2001. PMID: 11532146 - Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth.
Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Ajona D, et al. J Immunol. 2007 May 1;178(9):5991-8. doi: 10.4049/jimmunol.178.9.5991. J Immunol. 2007. PMID: 17442984 - Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.
Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Bützow R, Zipfel PF, Meri S. Junnikkala S, et al. Br J Cancer. 2002 Nov 4;87(10):1119-27. doi: 10.1038/sj.bjc.6600614. Br J Cancer. 2002. PMID: 12402151 Free PMC article. - Complement control protein factor H: the good, the bad, and the inadequate.
Ferreira VP, Pangburn MK, Cortés C. Ferreira VP, et al. Mol Immunol. 2010 Aug;47(13):2187-97. doi: 10.1016/j.molimm.2010.05.007. Mol Immunol. 2010. PMID: 20580090 Free PMC article. Review. - Tuning the Functionality by Splicing: Factor H and Its Alternative Splice Variant FHL-1 Share a Gene but Not All Functions.
Mannes M, Dopler A, Huber-Lang M, Schmidt CQ. Mannes M, et al. Front Immunol. 2020 Oct 15;11:596415. doi: 10.3389/fimmu.2020.596415. eCollection 2020. Front Immunol. 2020. PMID: 33178228 Free PMC article. Review.
Cited by
- Complement in Metastasis: A Comp in the Camp.
Ajona D, Ortiz-Espinosa S, Pio R, Lecanda F. Ajona D, et al. Front Immunol. 2019 Apr 3;10:669. doi: 10.3389/fimmu.2019.00669. eCollection 2019. Front Immunol. 2019. PMID: 31001273 Free PMC article. Review. - Exploration of the molecular biological mechanisms and review of postoperative radiotherapy cases in tenosynovial giant cell tumors.
Zhang T, Zeng B, Liu K, Zeng Q, Wang N, Peng L, Qiu H, Chen X, Wang L. Zhang T, et al. Front Oncol. 2024 Mar 14;14:1331815. doi: 10.3389/fonc.2024.1331815. eCollection 2024. Front Oncol. 2024. PMID: 38549939 Free PMC article. - Complement System Part II: Role in Immunity.
Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Merle NS, et al. Front Immunol. 2015 May 26;6:257. doi: 10.3389/fimmu.2015.00257. eCollection 2015. Front Immunol. 2015. PMID: 26074922 Free PMC article. Review. - Drivers and regulators of humoral innate immune responses to infection and cancer.
Kumar D, Romero Y, Schuck KN, Smalley H, Subedi B, Fleming SD. Kumar D, et al. Mol Immunol. 2020 May;121:99-110. doi: 10.1016/j.molimm.2020.03.005. Epub 2020 Mar 18. Mol Immunol. 2020. PMID: 32199212 Free PMC article. Review. - Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.
Boligan KF, Mesa C, Fernandez LE, von Gunten S. Boligan KF, et al. Cell Mol Life Sci. 2015 Apr;72(7):1231-48. doi: 10.1007/s00018-014-1799-5. Epub 2014 Dec 7. Cell Mol Life Sci. 2015. PMID: 25487607 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous